Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma - Authors' reply

Lancet Oncol. 2023 Jan;24(1):e1-e2. doi: 10.1016/S1470-2045(22)00740-9.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Carcinoma, Renal Cell* / drug therapy
  • Combined Modality Therapy
  • Humans
  • Kidney Neoplasms* / drug therapy

Substances

  • pembrolizumab
  • Antibodies, Monoclonal, Humanized